keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium-90

keyword
https://www.readbyqxmd.com/read/28105342/five-percent-dextrose-maximizes-dose-delivery-of-yttrium-90-resin-microspheres-and-reduces-rates-of-premature-stasis-compared-to-sterile-water
#1
Mary Ellen Koran, Samantha Stewart, Jennifer C Baker, Andrew J Lipnik, Fil Banovac, Reed A Omary, Daniel B Brown
Resin Yttrium-90 (Y90) microspheres have historically been infused using sterile water (H2O). In 2013, recommendations expanded to allow delivery with 5% dextrose in water (D5W). In this retrospective study, we hypothesized that D5W would improve Y90 delivery with a lower incidence of stasis. We reviewed 190 resin Y90 infusions using H2O (n=137) or D5W (n=53). Y90 dosimetry was calculated using the body surface area method. Infusion was halted if intra-arterial stasis was fluoroscopically identified prior to clearing the vial...
December 2016: Biomedical Reports
https://www.readbyqxmd.com/read/28078375/assessing-intra-arterial-complications-of-planning-and-treatment-angiograms-for-y-90-radioembolization
#2
Osman Ahmed, Mikin V Patel, Abdulrahman Masrani, Bradford Chong, Mohammed Osman, Jordan Tasse, Jayesh Soni, Ulku Cenk Turba, Bulent Arslan
PURPOSE: To report hepatic arterial-related complications encountered during planning and treatment angiograms for radioembolization and understand any potential-associated risk factors. MATERIALS AND METHODS: 518 mapping or treatment angiograms for 180 patients with primary or metastatic disease to the liver treated by Yttrium-90 radioembolization between 2/2010 and 12/2015 were retrospectively reviewed. Intra-procedural complications were recorded per SIR guidelines...
January 11, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28078116/pretreatment-tumor-volume-as-a-prognostic-factor-in-metastatic-colorectal-cancer-treated-with-selective-internal-radiation-to-the-liver-using-yttrium-90-resin-microspheres
#3
Neha Bhooshan, Navesh K Sharma, Shahed Badiyan, Adeel Kaiser, Fred M Moeslein, Young Kwok, Pradip P Amin, Svetlana Kudryasheva, Michael D Chuong
BACKGROUND: Yttrium-90 ((90)Y)-resin microspheres can prolong intrahepatic disease control and improve overall survival (OS) in patients with metastatic colorectal cancer (CRC). Prognostic factors for improved outcomes in patients undergoing selective internal radiation therapy (SIRT) have been studied, but the relationship between pre-SIRT liver tumor volume and outcomes has not well described. METHODS: We retrospectively reviewed the records of patients with metastatic CRC who were treated at our institution with (90)Y-resin microspheres...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28059929/hepatic-progression-free-and-overall-survival-after-regional-therapy-to-the-liver-for-metastatic-melanoma
#4
Andrea M Abbott, Matthew P Doepker, Youngchul Kim, Matthew C Perez, Cassandra Gandle, Kerry L Thomas, Junsung Choi, Ravi Shridhar, Jonathan S Zager
OBJECTIVES: Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) were evaluated. MATERIALS AND METHODS: A retrospective review of patients with liver metastases from cutaneous or uveal melanoma treated with yttrium-90 (Y90), chemoembolization (CE), or percutaneous hepatic perfusion (PHP) was conducted. RESULTS: Thirty patients (6 Y90, 10 PHP, 12 CE, 1 PHP then Y90, 1 CE then PHP) were included...
January 4, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28047827/su-c-204-01-a-dosimetric-investigation-into-the-effects-of-yttrium-90-radioembolization-on-the-gi-tract-in-vivo-and-histological-analysis-in-an-animal-model
#5
A Pasciak, L Nodit, A Bourgeois, B Paxton, A Arepally, Y Bradley
PURPOSE: In Yttrium-90 (90Y) radioembolization, non-target embolization (NTE) to the stomach or small bowel can result in ulceration, a rare but difficult to manage clinical complication. However, dosimetric thresholds for toxicity to these tissues from radioembolization have never been evaluated in a controlled setting. We performed an analysis of the effect of 90Y radioembolization in a porcine model at different absorbed-dose endpoints. METHODS: Under approval of the University of Tennessee IACUC, 6 female pigs were included in this study...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047017/su-c-204-07-radiation-therapy-as-a-potential-treatment-for-obesity-initial-data-from-a-preclinical-investigation
#6
A Pasciak, Y Bradley, L Nodit, A Bourgeois, B Paxton, A Arepally
PURPOSE: To evaluate the feasibility of Yttrium-90 (90Y) radionuclide therapy as a potential treatment for obesity in a porcine model. As the only appetite-stimulating hormone, localized targeting of ghrelin-producing X/A cells in the fundus of the stomach using 90Y may reduce serum ghrelin levels and decrease hunger. METHODS: Under approval of the University of Tennessee IACUC, 8 young female pigs aged 12-13 weeks and weighing 21.8-28.1 Kg were included in this study...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046479/we-ab-bra-05-pet-guided-delivery-quality-evaluation-of-yttrium-90-microsphere-radioembolizaton-for-hepatocellular-carcinoma-patients-the-optimal-sequence-of-radioembolizaton-and-chemoembolization-treatments
#7
M Lin, B Saboury
PURPOSE: Selective-internal-radiation-therapy (SIRT) and transarterial-chemoembolization (TACE) are commonly used for treatment of liver tumors. The use of TACE, which is macroembolic, prior to SIRT may cause hemodynamic changes in tumor vasculature that impair yttrium-90 (90Y) microsphere delivery to the targeted lesions. This work aims to quantify dosimetric tumor coverage using 90Y positron emission tomography (PET) dosimetry after SIRT alone compared to TACE followed by SIRT. METHODS: A total of 40 consecutive hepatocellular carcinoma (HCC) SIRT patients who had a post-SIRT 90Y PET/CT scan were evaluated...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28012419/formulation-and-purification-of-therapeutic-dose-of-90-y-labeled-peptides-some-interesting-radiochemistry-aspects
#8
Rubel Chakravarty, Sudipta Chakraborty, Ashutosh Dash
Yttrium-90 obtained from most of the (90)Sr/(90)Y generators contains (90)Sr impurity above permissible limit for human administration. A protocol has been optimized for formulation of therapeutic dose of (90)Y-DOTA-Tyr(3)-octreotate ((90)Y-DOTA-TATE) and removal of (90)Sr impurity from it. The radiochemical purity of (90)Y-DOTA-TATE was found to be >98% and it met the requirements for clinical use. The radiopharmaceutical was used in preliminary clinical investigation in patients with neuroendocrine tumors...
December 19, 2016: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28004357/yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases-a-prospective-cohort-study-on-circulating-angiogenic-factors-and-treatment-response
#9
C E N M Rosenbaum, A F van den Hoven, M N G J A Braat, M Koopman, M G E H Lam, B A Zonnenberg, H M Verkooijen, M A A J van den Bosch
BACKGROUND: Yttrium-90 radioembolization ((90)Y-RE) as a treatment for liver tumours induces radiation damage and hypoxia in liver tissue, which is also a trigger for systemic release of angiogenic factors, potentially stimulating tumour growth. We examined changes in circulating angiogenic factors following (90)Y-RE and investigated the association between response and angiogenic factors. In this prospective study, 42 patients with unresectable, chemorefractory metastatic colorectal cancer (CRCLM) were treated with (90)Y-RE...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/28004119/yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases-in-kras-wild-type-and-mutant-patients-clinical-and-ccfdna-studies
#10
E Janowski, O Timofeeva, S Chasovskikh, M Goldberg, A Kim, F Banovac, D Pang, A Dritschilo, K Unger
Patients with unresectable, chemo-refractory colorectal cancer liver metastases (CRCLM) have limited local treatment options. We report our institutional experience on the efficacy of resin-based yttrium-90 (90Y) radioembolization for the treatment of CRCLM and our findings on associated circulating cell-free DNA (ccfDNA) studies. A total of 58 patients treated with 90Y for CRCLM at the Medstar Georgetown University Hospital had a median survival of 6 months [95% confidence interval (CI), 4.55‑7.45 months] after treatment, with a 12-month survival rate of 33%...
January 2017: Oncology Reports
https://www.readbyqxmd.com/read/27996311/evaluating-the-application-of-tissue-specific-dose-kernels-instead-of-water-dose-kernels-in-internal-dosimetry-a-monte-carlo-study
#11
Maryam Khazaee Moghadam, Alireza Kamali Asl, Parham Geramifar, Habib Zaidi
PURPOSE: The aim of this work is to evaluate the application of tissue-specific dose kernels instead of water dose kernels to improve the accuracy of patient-specific dosimetry by taking tissue heterogeneities into consideration. MATERIALS AND METHODS: Tissue-specific dose point kernels (DPKs) and dose voxel kernels (DVKs) for yttrium-90 ((90)Y), lutetium-177 ((177)Lu), and phosphorus-32 ((32)P) are calculated using the Monte Carlo (MC) simulation code GATE (version 7)...
December 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27957721/computational-simulation-of-the-predicted-dosimetric-impact-of-adjuvant-yttrium-90-pet-ct-guided-percutaneous-ablation-following-radioembolization
#12
Alexander S Pasciak, Abigail Lin, Christos Georgiades, Laura K Findeiss, Shannon Kauffman, Yong C Bradley
BACKGROUND: (90)Y PET/CT post-radioembolization imaging has demonstrated that the distribution of (90)Y in a tumor can be non-uniform. Using computational modeling, we predicted the dosimetric impact of post-treatment (90)Y PET/CT-guided percutaneous ablation of the portions of a tumor receiving the lowest absorbed dose. A cohort of fourteen patients with non-resectable liver cancer previously treated using (90)Y radioembolization were included in this retrospective study. Each patient exhibited potentially under-treated areas of tumor following treatment based on quantitative (90)Y PET/CT...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27955832/transarterial-yttrium-90-radioembolization-treatment-of-patients-with-liver-dominant-metastatic-renal-cell-carcinoma
#13
Bela Kis, Jehan Shah, Junsung Choi, Ghassan El-Haddad, Jennifer Sweeney, Benjamin Biebel, Eric Mellon, Jessica M Frakes, Sarah E Hoffe, Mayer N Fishman, Ravi Shridhar
PURPOSE: To evaluate safety and efficacy of transarterial hepatic radioembolization treatment of patients with liver-dominant metastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: From July 2010 to December 2014, 18 patients with liver-dominant metastatic RCC were treated with yttrium-90 glass microsphere radioembolization. Retrospective review of medical records and imaging studies was performed to evaluate toxicities, treatment response, and overall survival...
December 7, 2016: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/27890462/radiation-pneumonitis-following-hepatic-yttrium-90-radioembolization
#14
Horacio Matías Castro, Esteban Javier Wainstein, Joaquin Maritano Furcada
No abstract text is available yet for this article.
November 24, 2016: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/27884683/yttrium-90-radioembolization-with-resin-microspheres-without-routine-embolization-of-the-gastroduodenal-artery
#15
Thomas J Ward, John D Louie, Daniel Y Sze
PURPOSE: To evaluate safety of resin microsphere radioembolization (RE) without prophylactic embolization of the gastroduodenal artery (GDA). MATERIALS AND METHODS: Between July 2013 and April 2015, all patients undergoing RE with resin microspheres for liver-dominant metastatic disease were treated without routine embolization of the GDA. Selective embolization of distal hepaticoenteric vessels was performed if identified by digital subtraction angiography, cone-beam computed tomography, or technetium-99m macroaggregated albumin scintigraphy...
November 21, 2016: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/27878478/liver-resection-after-selective-internal-radiation-therapy-with-yttrium-90-is-safe-and-feasible-a-bi-institutional-analysis
#16
G Paul Wright, J Wallis Marsh, Manish K Varma, Michael G Doherty, David L Bartlett, Mathew H Chung
BACKGROUND: Treatment with yttrium-90 (Y90) microspheres has emerged as a viable liver-directed therapy for patients with unresectable tumors and those outside transplantation criteria. A select number of patients demonstrate a favorable response and become candidates for surgical resection. METHODS: Patients who underwent selective internal radiation therapy (SIRT) with Y90 microspheres at two institutions were reviewed. Patients who underwent liver resection were included in the study...
November 22, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27875761/prognostic-value-of-post-yttrium-90-radioembolization-therapy-18f-fluorodeoxyglucose-positron-emission-tomography-in-patients-with-liver-tumors
#17
Sebastian Obrzut, Kevin McCammack, Karam W Badran, Anthony Balistreri, Evan Ou, Brian J Nguyen, Carl K Hoh, Steven C Rose
OBJECTIVE: This study assessed the benefit of post-therapy (18)F-FDG PET/CT versus CT alone in identifying malignant liver tumor progression following radioembolization with Y-90 microspheres. METHODS: 24 patients with 44 liver tumors underwent CT imaging pre-radioembolization and PET/CT post-radioembolization. Predictive value of Response Evaluation Criteria in Solid Tumors (RECIST 1.1), The World Health Organization (WHO), mRECIST and European Association for the Study of the Liver (EASL) with PET/CT versus CT alone was assessed...
November 16, 2016: Clinical Imaging
https://www.readbyqxmd.com/read/27870679/new-developments-in-interventional-oncology-liver-metastases-from-colorectal-cancer
#18
Joseph R Kallini, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ahsun Riaz, Robert J Lewandowski, Riad Salem
Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90)...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27826686/resin-based-yttrium-90-microspheres-for-unresectable-and-failed-first-line-chemotherapy-intrahepatic-cholangiocarcinoma-preliminary-results
#19
Zhongzhi Jia, Ricardo Paz-Fumagalli, Gregory Frey, David M Sella, J Mark McKinney, Weiping Wang
PURPOSE: To evaluate the value of resin-based yttrium-90 ((90)Y) radioembolization for unresectable and failed first-line chemotherapy (cisplatin plus gemcitabine) intrahepatic cholangiocarcinoma (ICC). METHODS: From February 2006 to September 2015, a retrospective study was conducted of all patients who underwent resin-based (90)Y therapy for unresectable and failed first-line chemotherapy ICC. Tumor response was assessed using modified RECIST criteria; side effects were assessed using Common Terminology Criteria for Adverse Events version 4...
November 8, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27821083/single-administration-of-selective-internal-radiation-therapy-versus-continuous-treatment-with-sorafenib-in-locally-advanced-hepatocellular-carcinoma-sirvenib-study-protocol-for-a-phase-iii-randomized-controlled-trial
#20
Mihir Gandhi, Su Pin Choo, Choon Hua Thng, Say Beng Tan, Albert Su Chong Low, Peng Chung Cheow, Anthony Soon Whatt Goh, Kiang Hiong Tay, Richard Hoau Gong Lo, Brian Kim Poh Goh, Jen San Wong, David Chee Eng Ng, Khee Chee Soo, Wei Ming Liew, Pierce K H Chow
BACKGROUND: Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation. For patients not eligible for such options, prognosis is poor. Sorafenib and Selective Internal Radiation Therapy (SIRT) are clinically proven treatment options in patients with unresectable HCC, and this study aims to assess overall survival following either SIRT or Sorafenib therapy for locally advanced HCC patients...
November 7, 2016: BMC Cancer
keyword
keyword
33486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"